Article
Oncogenic EGFR rewires STING-TBK1 signalosomes to license DNA damage tolerance in NSCLC.
The EMBO journal - 1 Aug 2026
Shen Qin, Mei Chen, Chen Yidan, Zhang Qian, Wu Qingzhe, Yu Xinyuan, Zhang Fei, Liu Shengduo, Chen Chen, Ye Cunqi, Zhang Qi, Feng Xin-Hua, Shen Li, Song Hai, Liang Tingbo, Song Penghong, Xia Bing, Xu Pinglong
Abstract excerpt
EGFR hotspot mutations (mEGFR), including primary L858R, exon 19 deletion, and secondary T790M, are pivotal oncogenic drivers in human non-small cell lung cancer (NSCLC). At the same time, NSCLC resistance to third-generation tyrosine kinase inhibitors (TKIs) is a major clinical challenge and remains mechanistically unresolved. Here, we uncover a previously unrecognized tumor cell-intrinsic mechanism in which...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.